文献速递类风湿关节炎

PF-05280586(一种潜在利妥昔单抗生物类似药)与利妥昔单抗在活动性类风湿关节炎受试者中的扩展研究

Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-01-01

这项扩展研究为已参加PF-05280586药代动力学相似性研究至少16周的活动性类风湿关节炎受试者提供持续治疗,评估从利妥昔单抗参照产品单次转换至PF-05280586后的总体药代动力学、药效学、免疫原性、安全性和耐受性。结果显示各组药物浓度无显著差异,CD19+ B细胞耗竭组间变异小,转换后免疫原性未增加,安全性和耐受性可接受,疗效反应持续至研究结束。

要点

  • 从利妥昔单抗参照产品单次转换至PF-05280586后未增加免疫原性。
  • 各组药物浓度和CD19+ B细胞耗竭无显著差异。
  • PF-05280586长期安全性和耐受性可接受,疗效反应持续。

核心结论

  • 研究显示从利妥昔单抗参照产品单次转换至PF-05280586后安全、耐受性和免疫原性可接受,且单次转换未增加免疫原性。

研究设计与样本

  • 扩展研究纳入母研究中已治疗至少16周的活动性类风湿关节炎受试者,提供不超过3个额外疗程的PF-05280586治疗,可伴或不伴从欧洲利妥昔单抗(MabThera)或美国利妥昔单抗(Rituxan)单次转换至PF-05280586。
  • 每个疗程包括2次静脉输注(第1天和第15天各1,000 mg,间隔24周[±8周])。
  • 母研究220例受试者中185例被随机化并纳入本扩展研究。

主要发现

  • 各组间及跨疗程药物浓度无显著差异,组间CD19+ B细胞耗竭变异小。
  • 输注相关反应与抗药抗体之间无 apparent 关系,伴或不伴从利妥昔单抗参照产品单次转换至PF-05280586。
  • 所有组PF-05280586长期安全性和耐受性可接受,长达96周,治疗中出现的不良事件发生率低,与单次药物转换无关。
  • 低疾病活动度评分和疾病活动度评分缓解的受试者百分比在所有时间点各组相似,反应持续至研究结束。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This extension study provided continued treatment to subjects with active rheumatoid arthritis who had participated for ≥16 weeks in a pharmacokinetic similarity study of PF-05280586 (potential rituximab biosimilar). Objectives were to evaluate overall pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of PF-05280586 after transition from rituximab reference products to PF-05280586, and follow-up of biomarker and efficacy assessments. METHODS: Subjects were offered ≤3 additional courses of treatment of PF-05280586, with or without a single transition from rituximab in Europe (rituximab-EU; MabThera) or the US (rituximab-US; Rituxan) to PF-05280586. Each course comprised 2 intravenous infusions (1,000 mg on days 1 and 15, separated by 24 weeks [± 8 weeks]). RESULTS: Of 220 subjects in the parent study, 185 were randomized and included in this study. There were no notable differences in drug concentrations between groups or across courses, with little variation in depletion of CD19+ B cells between groups, and no apparent relationship between infusion-related reactions and antidrug antibodies with or without single transition from rituximab reference products to PF-05280586. Long-term safety and tolerability of PF-05280586 was acceptable in all groups for up to 96 weeks, with a low incidence of treatment-emergent adverse events independent of single drug transition. The percentage of subjects with a low disease activity score and disease activity score remission was similar across groups for all time points, and responses were sustained until end of study. CONCLUSION: This study demonstrated acceptable safety, tolerability, and immunogenicity, with or without single transition from rituximab reference products to PF-05280586, without increased immunogenicity on single transition.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Cohen SB, Burgos-Vargas R, Emery P, et al. Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018. PMID: 29692005. doi:10.1002/acr.23586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。